Всемирная психиатрия. №2 2018

Недостаточность доказательств относительно предпочтения специфичных профилактических методик при психозах: сетевой метаанализ

Cathy Davies1, Andrea Cipriani2, John P.A. Ioannidis3-7, Joaquim Radua1,8,9, Daniel Stahl10, Umberto Provenzani1,11, Philip McGuire12,13, Paolo Fusar-Poli1,11,13,14

1Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK; 2Department of Psychiatry, University of Oxford, and Oxford Health NHS Foundation Trust, Oxford, UK; 3Department of Medicine, Stanford Prevention Research Center, Stanford, CA, USA; 4Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA; 5Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA; 6Meta-Research Innovation Center at Stanford, Stanford University, Stanford, CA, USA; 7Department of Statistics, Stanford University School of Humanities and Sciences, Stanford, CA, USA; 8FIDMAG Germanes Hospitalaries, CIBERSAM, Sant Boi de Llobregat, Spain; 9Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden; 10Biostatistics Department, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK; 11Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; 12Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK; 13National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre, London, UK; 14OASIS Service, South London and Maudsley NHS Foundation Trust, London, UK

Стр. 194-205

1668 просмотров

Опубликовано: 12 ноября 2018

Аннотация / Abstract

a:2:{s:4:"TEXT";s:65527:"a:2:{s:4:"TYPE";s:4:"HTML";s:4:"TEXT";s:75107:"Перевод: Тверская Е.И. (Москва) Редактура: к.м.н. Бойко А.С. (Томск) Предотвращение развития психозов у пациентов с высоким клиническим риском может стать перспективным направлением для превентивного улучшения состояния при наиболее тяжелом психическом расстройстве. Тем не менее до сих пор остается неизвестным, какие преимущества имеет каждая из профилактических интервенций в соотношении с другими имеющимися в настоящее время вариантами лечения. Целью данного исследования была количественная оценка согласованности и величины эффектов конкретных профилактических интервенций при психозах и сравнение различных методов лечения при помощи метаанализа. Были исследованы базы данных PsycINFO и Web of Science, Кокрановский центральный регистр контролируемых исследований и неопубликованная/серая литература (до 18 июля 2017 г. включительно) для отбора рандомизированных контролируемых исследований, проведенных у лиц с высоким клиническим риском развития психоза, сравнения различных типов интервенции и отчетности по переходу к психозу. Два рецензента независимо извлекли данные. Данные были синтезированы с использованием сетевого метаанализа. Первичным исходом считался переход к психозу в разные моменты времени, вторичным исходом – приемлемость лечения (учитывалось исключение по какой-либо причине). Размер эффекта представлен показателем отношения шансов и 95% доверительным интервалом. Шестнадцать исследований (2035 пациентов, 57% мужчин, средний возраст 20,1 года) свидетельствовали о риске развития психоза. Сравнивались следующие методы лечения: интервенции, основанные на потребностях (needs-based interventions – NBI); омега-3+NBI; зипразидон+NBI; олазапин+NBI; арипипразол+NBI; интегральные психологические интервенции; семейная терапия+NBl; D-серин+NBI; когнитивная поведенческая терапия, протокол French и Morrison (CBT-F)+NBI; CBT-F+рисперидон+NBI; и протокол van der Gaag для когнитивной поведенч...

Перевод: Тверская Е.И. (Москва) Редактура: к.м.н. Бойко А.С. (Томск) Предотвращение развития психозов у пациентов с высоким клиническим риском может стать перспективным направлением для превентивного улучшения состояния при наиболее тяжелом психическом расстройстве. Тем не менее до сих пор остается неизвестным, какие преимущества имеет каждая из профилактических интервенций в соотношении с другими имеющимися в настоящее время вариантами лечения. Целью данного исследования была количественная оценка согласованности и величины эффектов конкретных профилактических интервенций при психозах и сравнение различных методов лечения при помощи метаанализа. Были исследованы базы данных PsycINFO и Web of Science, Кокрановский центральный регистр контролируемых исследований и неопубликованная/серая литература (до 18 �...

Материал для специалистов

Полный текст статьи доступен только зарегистрированным пользователям.

Вход / Регистрация

1. Fusar-Poli P. The clinical high-risk state for psychosis (CHR-P), Version II. Schizophr Bull 2017;43:44-7.
2. Fusar-Poli P, Borgwardt S, Bechdolf A et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 2013;70:10720
3. Falkenberg I, Valmaggia L, Byrnes M et al. Why are help-seeking subjects at ultra-high risk for psychosis help-seeking? Psychiatry Res 2015;228:808-15.
4. Webb JR, Addington J, Perkins DO et al. Speciﬁcity of incident diagnostic outcomes in patients at clinical high risk for psychosis. Schizophr Bull 2015;41:1066-75.
5. Fusar-Poli P, Rutigliano G, Stahl D et al. Long-term validity of the At Risk Mental State (ARMS) for predicting psychotic and non-psychotic mental disorders. Eur Psychiatry 2017;42:49-54.
6. Fusar-Poli P, Cappucciati M, Borgwardt S et al. Heterogeneity of psychosis risk within individuals at clinical high risk. JAMA Psychiatry 2016;73:113-20
7. Millan MJ, Andrieux A, Bartzokis G et al. Altering the course of schizophrenia: progress and perspectives. Nat Rev Drug Discov 2016;15:485-515.
8. Fusar-Poli P, McGorry P, Kane JM. Improving outcomes of ﬁrst episode psychosis. World Psychiatry 2017;16:251-65.
9. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. Guideline CG178. London: National Institute for Health and Care Excellence, 2014.
10. Schmidt SJ, Schultze-Lutter F, Schimmelmann BG et al. EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry 2015;30:388-404.
11. Taylor M, Perera U. NICE CG178 psychosis and schizophrenia in adults: treatment and management – an evidence-based guideline? Br J Psychiatry 2015;206:357-9.
12. Preti A, Cella M. Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr Res 2010;123:30-6.
13. Deas G, Kelly C, Hadjinicolaou AV et al. An upd ate on: meta-analysis of medical and non-medical treatments of the prodromal phase of psychotic illness in at risk mental states. Psychiatr Danub 2016;28:31-8.
14. Hutton P, Taylor PJ. Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis. Psychol Med 2014;44:44968.
15. Stafford MR, Jackson H, Mayo-Wilson E et al. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 2013;346:f185.
16. Kelly C, Hadjinicolaou AV, Holt C et al. Meta-analysis of medical and non-medical treatments of the prodromal phase of psychotic illness in at-risk mental states. Psychiatr Danub 2010;22:56-62.
17. Marshall M, Rathbone J. Early intervention for psychosis. Cochrane Database Syst Rev 2011;6:CD004718.
18. Van Der Gaag M, Smit F, Bechdolf A et al. Preventing a ﬁrst episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res 2013;149:56-62.
19. Stafford MR, Jackson H, Mayo-Wilson E et al. Errata: Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 2013;346:f762.
20. Nordentoft M, Thorup A, Petersen L et al. Transition rates from schizotypal disorder to psychotic disorder for ﬁrst-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res 2006;83:29-40.
21. Kempton MJ, Bonoldi I, Valmaggia L et al. Speed of psychosis progression in people at ultra-high clinical risk. JAMA Psychiatry 2015;72:622-3.
22. Ioannidis JPA. The mass production of redundant, misleading, and conﬂicted systematic reviews and meta-analyses. Milbank Q 2016;94:485-514.
23. Hartmann JA, McGorry PD, Schmidt SJ et al. Opening the black box of cognitive-behavioural case management in clients with ultra-high risk for psychosis. Psychother Psychosom 2017;86:292-9.
24. Mueser KT, Glynn SM, Meyer-Kalos PS. What are the key ingredients of optimal psychosocial treatment for persons recovering from a ﬁrst episode of psychosis? World Psychiatry 2017;16:266-7.
25. Cipriani A, Higgins JPT, Geddes JR et al. Conceptual and technical challenges in network meta-analysis. Ann Intern Med 2013;159:130-7.
26. Thorlund K, Mills EJ. Sample size and power considerations in network meta-analysis. Syst Rev 2012;1:41.
27. Kanters S, Ford N, Druyts E et al. Use of network meta-analysis in clinical guidelines. Bull World Health Organ 2016;94:782-4.
28. Leucht S, Chaimani A, Cipriani AS et al. Network meta-analyses should be the highest level of evidence in treatment guidelines. Eur Arch Psychiatry Clin Neurosci 2016;266:477-80.
29. Hutton B, Salanti G, Caldwell DM et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777-84.
30. Addington J, Epstein I, Liu L et al. A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res 2011;125:54-61.
31. McGorry PD, Yung AR, Phillips LJ et al. Randomized controlled trial of interventions designed to reduce the risk of progression to ﬁrst-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002;59:921-8.
32. Yung AR, McGorry PD, Francey SM et al. PACE: a specialised service for young people at risk of psychotic disorders. Med J Aust 2007;187:S43-6.
33. Amminger GP, Schäfer MR, Papageorgiou K et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders. Arch Gen Psychiatry 2010;67:146-54.
34. French P, Morrison A. Early detection and cognitive therapy for people at high risk of developing psychosis. Chichester: Wiley, 2004.
35. Beck AT. Cognitive therapy and the emotional disorders. Madison: International University Press, 1976.
36. Morrison AP, French P, Walford L et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 2004;185:291-7.
37. Van der Gaag M, Nieman DH, Rietdijk J et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull 2012;38:1180-8.
38. Rietdijk J, Dragt S, Klaassen R et al. A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an at risk mental state for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial. Trials 2010;11:30.
39. Bechdolf A, Wagner M, Ruhrmann S et al. Preventing progression to ﬁrstepisode psychosis in early initial prodromal states. Br J Psychiatry 2012;200:22-9.
40. Bechdolf A, Puetzfeld V, Guettgemanns J et al. Cognitive behaviour therapy for people at-risk of psychosis. A treatment manual. Bern: Huber, 2010.
41. Miklowitz DJ, O’Brien MP, Schlosser DA et al. Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry 2014;53:848-58
42. Yung AR, Yuen HP, McGorry PD et al. Mapping the onset of psychosis: the Comprehensive Assessment of At Risk Mental States (CAARMS). Aust N Z J Psychiatry 2005;39:964-71.
43. McGlashan T, Walsh B, Woods S. The psychosis-risk syndrome: handbook for diagnosis and follow-up. Oxford: Oxford University Press, 2010.
44. Fusar-Poli P, Cappucciati M, Rutigliano G et al. Towards a standard psychometric diagnostic interview for subjects at ultra high risk of psychosis: CAARMS versus SIPS. Psychiatry J 2016;2016:7146341.
45. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
46. Overall J, Gorham D. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 1988;24:97-9.
47. Haefner H, Bechdolf A, Klosterkotter J et al. Early detection and intervention in psychosis. A practise handbook. Stuttgart: Schattauer, 2011.
48. Cipriani A, Zhou X, Del Giovane C et al. Comparative efﬁcacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet 2016;388:881-90.
49. Fusar-Poli P, Cappucciati M, Bonoldi I et al. Prognosis of brief psychotic episodes: a meta-analysis. JAMA Psychiatry 2016;73:211-20.
50. Higgins JPT, Green S (eds). Cochrane handbook for systematic reviews of interventions version 5.1.0. http://handbook.cochrane.org
51. Guyot P, Ades A, Ouwens MJ et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 2012;12:9.
52. Radua J, Grunze H, Amann BL. Meta-analysis of the risk of subsequent mood episodes in bipolar disorder. Psychother Psychosom 2017;86:90-8.
53. Cipriani A, Furukawa TA, Salanti G et al. Comparative efﬁcacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network metaanalysis. Lancet 2018;391:1357-66.
54. Cipriani A, Furukawa TA, Salanti G et al. Comparative efﬁcacy and acceptability of 12 new-generation antidepressants: a multiple-treatments metaanalysis. Lancet 2009;373:746-58.
55. Miura T, Noma H, Furukawa TA et al. Comparative efﬁcacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry 2014;1:351-9.
56. Higgins JPT, Altman DG, Gøtzsche PC et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343: d5928.
57. Furukawa TA, Salanti G, Atkinson LZ et al. Comparative efﬁcacy and acceptability of ﬁrst-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network metaanalysis. BMJ Open 2016;6:e010919.
58. Chaimani A, Higgins JPT, Mavridis D et al. Graphical tools for network meta-analysis in STATA. PLoS One 2013;8:e76654.
59. Salanti G, Del Giovane C, Chaimani A et al. Evaluating the quality of evidence from a network meta-analysis. PLoS One 2014;9:e99682.
60. Guyatt G, Oxman AD, Sultan S et al. GRADE guidelines: 11. Making an overall rating of conﬁdence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol 2013;66:151-7.
61. Chaimani A, Salanti G. Visualizing assumptions and results in network meta-analysis: the network graphs package. Stata J 2015;15:905-50.
62. Higgins JPT, Jackson D, Barrett JK et al. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 2012;3:98-110.
63. White IR. Multivariate random-effects meta-regression: updates to mvmeta. Stata J 2011;11:255-70.
64. Mavridis D, Giannatsi M, Cipriani A et al. A primer on network metaanalysis with emphasis on mental health. Evid Based Ment Health 2015;18:40-6.
65. Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71.
66. Mbuagbaw L, Rochwerg B, Jaeschke R et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev 2017;6:79.
67. Chaimani A, Salanti G, Leucht S et al. Common pitfalls and mistakes in the se t-up, analysis and interpretation of results in network meta-analysis: what clinicians should look for in a published article. Evid Based Ment Health 2017;20:88-94.
68. Wilson RP, Patel R, Bhattacharyya S. Do fewer males present to clinical high-risk services for psychosis relative to ﬁrst-episode services? Early Interv Psychiatry 2016;11:429-35.
69. Schultze-Lutter F, Hubl D, Schimmelmann BG et al. Age effect on prevalence of ultra-high risk for psychosis symptoms: replication in a clinical sample of an early detection of psychosis service. Eur Child Adolesc Psychiatry 2017;26:1401-5.
70. Fusar-Poli P, Frascarelli M, Valmaggia L et al. Antidepressant, antipsychotic and psychological interventions in subjects at high clinical risk for psychosis: OASIS 6-year naturalistic study. Psychol Med 2015;45:132739.
71. Fusar-Poli P, Papanastasiou E, Stahl D et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebocontrolled trials. Schizophr Bull 2015;41:892-9.
72. Bechdolf A, Müller H, Stützer H et al. PREVENT: a randomized controlled trial for the prevention of ﬁrst-episode psychosis comparing cognitivebehavior therapy (CBT), clinical management, and aripiprazole combined and clinical management and placebo combined. Schizophr Bull 2017;43(Suppl.1):S56-7.
73. Cadenhead K, Addington J, Cannon T et al. Omega-3 fatty acid versus placebo in a clinical high-risk sample from the North American Prodrome Longitudinal Studies (NAPLS) consortium. Schizophr Bull 2017;43(Suppl.1):S16.
74. Kantrowitz JT, Woods SW, Petkova E et al. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. Lancet Psychiatry 2015;2:403-12.
75. McGlashan TH, Zipursky RB, Perkins D et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006;163:790-9.
76. McGorry PD, Nelson B, Markulev C et al. Effect of ω-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders. The NEURAPRO randomized controlled trial. JAMA Psychiatry 2017;74:19-27.
77. Morrison AP, French P, Stewart SL et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ 2012;344:e2233.
78. Stain HJ, Bucci S, Baker AL et al. A randomised controlled trial of cognitive behaviour therapy versus non-directive reﬂective listening for young people at ultra high risk of developing psychosis: the detection and evaluation of psychological therapy (DEPTh) trial. Schizophr Res 2016;176: 212-9.
79. Woods S, Saksa J, Compton M et al. Effects of ziprasidone versus placebo in patients at clinical high risk for psychosis. Schizophr Bull 2017;43 (Suppl.1):S58.
80. Woods SW. Ziprasidone in the psychosis prodrome (ZIP). ClinicalTrials.gov, NCT00635700.
81. Yung AR, Phillips LJ, Nelson B et al. Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. J Clin Psychiatry 2011;72:430-40.
82. McGorry PD, Nelson B, Phillips LJ et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelvemonth outcome. J Clin Psychiatry 2013;74:349-56.
83. Bechdolf A, Phillips LJ, Francey SM et al. Recent approaches to psychological interventions for people at risk of psychosis. Eur Arch Psychiatry Clin Neurosci 2006;256:159-73.
84. Flach C, French P, Dunn G et al. Components of therapy as mechanisms of change in cognitive therapy for people at risk of psychosis: analysis of the EDIE-2 trial. Br J Psychiatry 2015;207:123-9.
85. Leichsenring F, Steinert C. Is cognitive behavioral therapy the gold standard for psychotherapy? The need for plurality in treatment and research. JAMA 2017;318:1323-4.
86. Mulder R, Murray G, Rucklidge J. Common versus speciﬁc factors in psychotherapy: opening the black box. Lancet Psychiatry 2017;4:953-62.
87. Porter RJ, Boden JM, Miskowiak K et al. Failure to publish negative results: a systematic bias in psychiatric literature. Aust N Z J Psychiatry 2017;51:212-4.
88. Flint J, Cuijpers P, Horder J et al. Is there an excess of signiﬁcant ﬁndings in published studies of psychotherapy for depression? Psychol Med 2015; 45:439-46
89. Ioannidis JPA. Excess signiﬁcance bias in the literature on brain volume abnormalities. Arch Gen Psychiatry 2011;68:773-80.
90. Carvalho AF, Köhler CA, Fernandes BS et al. Bias in emerging biomarkers for bipolar disorder. Psychol Med 2016;46:2287-97.
91. David SP, Ware JJ, Chu IM et al. Potential reporting bias in fMRI studies of the brain. PLoS One 2013;8:e70104.
92. Fusar-Poli P, Radua J, Frascarelli M et al. Evidence of reporting biases in voxel-based morphometry (VBM) studies of psychiatric and neurological disorders. Hum Brain Mapp 2014;35:3052-65.
93. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995;311:485.
94. Ruhrmann S, Bechdolf A, Kühn KU et al. Acute effects of treatment for prodromal symptoms for people putatively in late initial prodromal state of psychosis. Br J Psychiatry 2007;191:88-96.
95. Fusar-Poli P. Negative psychosis prevention trials. JAMA Psychiatry 2017;74:651.
96. Devoe DJ, Peterson A, Addington J. Negative symptom interventions in youth at risk of psychosis: a systematic review and network meta-analysis. Schizophr Bull (in press).
97. Fusar-Poli P, Van Os J. Lost in transition: setting the psychosis threshold in prodromal research. Acta Psychiatr Scand 2013;127:248-52.
98. Van Os J, Guloksuz S. A critique of the “ultra-high risk” and “transition” paradigm. World Psychiatry 2017;16:200-6.
99. Yung AR. Treatment of people at ultra-high risk for psychosis. World Psychiatry 2017;16:207-8.
100. Trinquart L, Attiche N, Bafeta A et al. Uncertainty in treatment rankings: reanalysis of network meta-analyses of randomized trials. Ann Intern Med 2016;164:666-73.
101. Kapur S, Phillips AG, Insel TR. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry 2012;17:1174-9.
102. PRONIA. Personalised prognostic tools for early psychosis management. www.pronia.eu.
103. NAPLS. The North American Prodrome Longitudinal Study. https://campuspress.yale.edu/napls/.
104. PSYSCAN. Translating neuroimaging ﬁndings from research into clinical practice. http://intranet.psyscan.eu/.
105. Fusar-Poli P, Cappucciati M, De Micheli A et al. Diagnostic and prognostic signiﬁcance of brief limited intermittent psychotic symptoms (BLIPS) in individuals at ultra high risk. Schizophr Bull 2017;43:48-56.
106. Fusar-Poli P, Tantardini M, De Simone S et al. Deconstructing vulnerability for psychosis: meta-analysis of environmental risk factors for psychosis in subjects at ultra high-risk. Eur Psychiatry 2017;40:65-75.
107. Fusar-Poli P, Schultze-Lutter F, Cappucciati M et al. The dark side of the moon: meta-analytical impact of recruitment strategies on risk enrichment in the clinical high risk state for psychosis. Schizophr Bull 2016;42:732-43.
108. Fusar-Poli P, Rutigliano G, Stahl D et al. Deconstructing pretest risk enrichment to optimize prediction of psychosis in individuals at clinical high risk. JAMA Psychiatry 2016;73:1260-7.
109. Fusar-Poli P. Why ultra high risk criteria for psychosis prediction do not work well outside clinical samples and what to do about it. World Psychiatry 2017;16:212-3.
110. Roccarina D, Majumdar A, Thorburn D et al. Management of people with intermediate-stage hepatocellular carcinoma: an attempted network metaanalysis. Cochrane Database Syst Rev 2017;3:CD011649.
111. Buzzetti E, Kalafateli M, Thorburn D et al. Interventions for hereditary haemochromatosis: an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:CD011647
112. Mantzoukis K, Rodríguez-Perálvarez M, Buzzetti E et al. Pharmacological interventions for acute hepatitis B infection: an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3: CD011645.
113. Desborough M, Hadjinicolaou AV, Chaimani A et al. Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review. Cochrane Database Syst Rev 2016;10:CD012055.

ЖУРНАЛЫ

ИНТЕРАКТИВ

СПЕЦИАЛИЗАЦИИ

ИЗДАНИЯ-ПАРТНЕРЫ

Недостаточность доказательств относительно предпочтения специфичных профилактических методик при психозах: сетевой метаанализ

Материал для специалистов

ЖУРНАЛЫ

ИНТЕРАКТИВ

СПЕЦИАЛИЗАЦИИ

ИЗДАНИЯ-ПАРТНЕРЫ

Недостаточность доказательств относительно предпочтения специфичных профилактических методик при психозах: сетевой метаанализ

Материал для специалистов

Con-Med Passport